First patient injected with new radiotherapy in phase 2b brain cancer trial
The first patient was dosed in a phase 2b clinical trial evaluating rhenium (186Re) obisbemed, a new injectable radiotherapy, for the treatment of recurrent glioblastoma, a type of brain cancer. Researchers conducting the ReSPECT-GBM trial will evaluate the safety, tolerability, distribution and efficacy of rhenium (186Re) obisbemed, according to a press release from Plus Therapeutics, …
First patient injected with new radiotherapy in phase 2b brain cancer trial Read More »